文献速递血栓与止血

COVID-19患者肝素诱导性血小板减少症的系统综述与荟萃分析

Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2021-01-01

该系统综述与荟萃分析通过检索多个数据库,评估COVID-19住院患者中肝素诱导性血小板减少症(HIT)的发生率及临床特征。纳入7项研究共5849例患者的荟萃分析显示HIT合并发生率为0.8%,治疗性肝素亚组(1.2%)高于预防性亚组(0.1%),危重症患者(2.2%)高于非危重症患者(0.1%)。19例确诊HIT患者从肝素启动至诊断的中位时间为13.5天,63%发生血栓栓塞。

要点

  • COVID-19住院患者HIT合并发生率为0.8%,与无COVID-19患者相当。
  • 治疗性肝素者HIT发生率1.2%,高于预防性肝素者的0.1%。
  • 危重症COVID-19患者HIT发生率2.2%,显著高于非危重症者的0.1%。

核心结论

  • COVID-19患者HIT发生率与无COVID-19患者相当,治疗性抗凝和危重症患者中发生率更高。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、EMBASE、Cochrane和medRxiv数据库。
  • 荟萃分析纳入7项研究共5849例住院COVID-19患者。
  • 对19例确诊HIT和1例自身免疫性HIT患者进行临床与实验室特征分析。

主要发现

  • 7项研究荟萃分析显示COVID-19患者HIT合并发生率为0.8%(95%CI 0.2%-3.2%;I2=89%)。
  • 治疗性肝素亚组HIT发生率为1.2%(95%CI 0.3%-3.9%;I2=65%),预防性亚组为0.1%(95%CI 0.0%-0.4%;I2=0%)。
  • 危重症患者HIT发生率为2.2%(95%CI 0.6%-8.3%;I2=72.5%),非危重症患者为0.1%(95%CI 0.0%-0.4%;I2=0%)。
  • 确诊HIT患者从肝素启动至诊断的中位时间为13.5天(IQR 10.75-16.25天)。

临床怎么用

  • COVID-19住院患者使用肝素时应监测HIT,尤其治疗性抗凝和危重症患者。
  • HIT诊断中位时间约13.5天,需关注肝素使用后的血小板变化和血栓事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin thromboprophylaxis is routinely administered during hospitalization for COVID-19. Because of the immune stimulation related to COVID-19, there is ongoing concern regarding a heightened incidence of heparin-induced thrombocytopenia (HIT). We performed a literature search using PubMed, EMBASE, Cochrane, and medRxiv database to identify studies that reported clinical and laboratory characteristics and/or the incidence of HIT in patients with COVID-19. The primary aim was to systematically review the clinical features and outcomes of patients with COVID-19 with confirmed HIT. The secondary objective was to perform a meta-analysis to estimate the incidence of HIT in hospitalized patients with COVID-19. A meta-analysis of 7 studies including 5849 patients revealed the pooled incidence of HIT in COVID-19 of 0.8% (95% confidence interval [CI], 0.2%-3.2%; I2 = 89%). The estimated incidences were 1.2% (95% CI, 0.3%-3.9%; I2 = 65%) vs 0.1% (95% CI, 0.0%-0.4%; I2 = 0%) in therapeutic vs prophylactic heparin subgroups, respectively. The pooled incidences of HIT were higher in critically ill patients with COVID-19 (2.2%; 95% CI, 0.6%-8.3%; I2 = 72.5%) compared with noncritically ill patients (0.1%; 95% CI, 0.0%-0.4%: I2 = 0%). There were 19 cases of confirmed HIT and 1 with autoimmune HIT for clinical and laboratory characterization. The median time from heparin initiation to HIT diagnosis was 13.5 days (interquartile range, 10.75-16.25 days). Twelve (63%) developed thromboembolism after heparin therapy. In conclusion, the incidence of HIT in patients with COVID-19 was comparable to patients without COVID-19, with higher incidences with therapeutic anticoagulation and in critically ill patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Uaprasert N, Tangcheewinsirikul N, Rojnuckarin P, et al. Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. Blood Adv. 2021. PMID: 34543382. doi:10.1182/bloodadvances.2021005314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。